3D Heart Models for Congenital Heart Disease
(IMMPACT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if 3D printed heart models can improve surgical planning for children with congenital heart disease (CHD) who require a ventricular assist device (VAD) to support heart function. Researchers will compare the outcomes of surgeries planned with 3D models to those without them to assess whether the models enhance surgical clarity and success. Children with CHD and heart failure who weigh more than 3 kilograms and are candidates for mechanical heart support may be suitable for this study. As an unphased trial, this study provides a unique opportunity for participants to contribute to innovative research that could enhance surgical planning and outcomes for future patients.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this 3D heart model is safe for surgical planning in children with congenital heart disease?
Research has shown that 3D printed heart models are safe because they are non-invasive and used for planning surgeries, not for treatment. Nothing is placed directly into the body. Studies have found that these models accurately replicate the heart's structure, aiding doctors in planning surgeries more effectively. This can result in safer and more precise procedures for patients with congenital heart disease, a condition present at birth that affects the heart's structure. No reports indicate problems directly caused by using these models, as they primarily assist doctors in visualizing and planning surgeries.12345
Why are researchers excited about this trial?
Researchers are excited about using 3D heart models for congenital heart disease because they offer a new level of precision in surgical planning. Unlike traditional 2D imaging, these 3D models provide a tangible, detailed view of the heart's structure, which can help surgeons better understand the specific sites for cannula and ventricular assist device (VAD) placement. This enhanced clarity could lead to more accurate surgeries and potentially better outcomes for patients.
What evidence suggests that a 3D heart model is effective for surgical planning in congenital heart disease?
Studies have shown that 3D printed heart models can greatly improve understanding of complex heart structures. In this trial, Group A will use 3D printed models for pre-VAD planning, potentially aiding doctors in better surgical planning by clearly indicating device placement. Research indicates that these models enhance surgical planning and execution. In education, 3D models have also helped medical students and doctors learn more about heart anatomy. These findings suggest that 3D printed models could lead to better outcomes for children needing heart surgery. Meanwhile, Group B will serve as the control group and will not use a 3D model.678910
Who Is on the Research Team?
Kanwal Farooqi, MD
Principal Investigator
Columbia University
Are You a Good Fit for This Trial?
This trial is for children over 3 kilograms with Congenital Heart Disease (CHD) and heart failure who are candidates for mechanical circulatory support. It's not suitable for those unable to tolerate a cardiac MRI or CT scan.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-surgical Planning
3D printed heart models are used for surgical planning in Group A, while Group B proceeds without the model
Surgical Intervention
Ventricular assist device (VAD) placement surgery is performed
Follow-up
Participants are monitored for safety and effectiveness after VAD placement, including assessment of cardiopulmonary bypass time
What Are the Treatments Tested in This Trial?
Interventions
- 3D model of heart
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator